Long-term safety and tolerability of dasatinib (BMS-354825) in subjects who experienced clinical benefit on protocol CA 180-002

Trial Profile

Long-term safety and tolerability of dasatinib (BMS-354825) in subjects who experienced clinical benefit on protocol CA 180-002

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2013

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Sep 2009 Bristol-Myers Squibb added as a trial sponsor as reported by ClinicalTrials.gov (NCT00978731).
    • 18 Sep 2009 Bristol-Myers Squibb added as a trial sponsor as reported by ClinicalTrials.gov (NCT00978731).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top